Clover Corp Ltd (ASX: CLV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clover Corp Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clover Corp Ltd (ASX: CLV)
Latest News
52-Week Lows
3 ASX shares sinking to 52-week lows today
Share Gainers
Why Bannerman, Clover, Polynovo, and Pro Medicus shares are pushing higher
Dividend Investing
5 ASX All Ords shares trading ex-dividend this week
Dividend Investing
Here are 3 ASX All Ords shares turning ex-dividend this week
Share Gainers
Why Clover, Select Harvests, Whitehaven Coal, and Woodside shares are storming higher
Share Gainers
3 ASX All Ordinaries shares defying today's rout to surge higher
Dividend Investing
Here are 5 ASX shares trading ex-dividend this week
Share Fallers
Clover (ASX:CLV) share price sinks 7% on FY 2021 results
Dividend Investing
2 ASX dividend shares that could provide steady income retirement
Share Market News
ASX investors couldn't get enough of meme stocks last week
Consumer Staples & Discretionary Shares
Will 2021 go down as the year A2 and other milk share prices turned sour?
Broker Notes
Top brokers name 3 ASX shares to buy today
Frequently Asked Questions
-
Yes, Clover Corporation has historically paid two fully franked shareholder dividends a year.
-
Clover Corporation generally pays its dividends in April and November.
-
No, Clover Corporation does not have a dividend reinvestment plan at the current time.
-
Clover Corporation listed on the ASX on 30 November 1999.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
21 Oct 2024 | $0.0075 | 100.00% | Final | 18 Nov 2024 |
30 Oct 2023 | $0.0075 | 100.00% | Final | 20 Nov 2023 |
05 Apr 2023 | $0.0075 | 100.00% | Interim | 27 Apr 2023 |
25 Oct 2022 | $0.0100 | 100.00% | Final | 22 Nov 2022 |
06 Apr 2022 | $0.0050 | 100.00% | Interim | 28 Apr 2022 |
25 Oct 2021 | $0.0050 | 100.00% | Final | 16 Nov 2021 |
07 Apr 2021 | $0.0050 | 100.00% | Interim | 29 Apr 2021 |
27 Oct 2020 | $0.0250 | 100.00% | Final | 18 Nov 2020 |
29 Oct 2019 | $0.0175 | 100.00% | Final | 20 Nov 2019 |
08 Apr 2019 | $0.0063 | 100.00% | Interim | 30 Apr 2019 |
29 Oct 2018 | $0.0125 | 100.00% | Final | 20 Nov 2018 |
09 Apr 2018 | $0.0050 | 100.00% | Interim | 01 May 2018 |
27 Oct 2017 | $0.0000 | 100.00% | Final | 20 Nov 2017 |
10 Apr 2017 | $0.0025 | 100.00% | Interim | 01 May 2017 |
27 Oct 2016 | $0.0050 | 100.00% | Final | 21 Nov 2016 |
11 Apr 2016 | $0.0025 | 100.00% | Interim | 02 May 2016 |
29 Nov 2010 | $0.0125 | 100.00% | Final | 15 Dec 2010 |
CLV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Clover Corp Ltd
Clover Corporation Limited (ASX: CLV) provides nutritional ingredients, particularly omega-3 and omega-6 fatty acids. The company is involved in the production of encapsulated powders, and research and product development of infant nutrition and functional food ingredients.
Clover Corporation offers Nu-MegaHi tuna oils for use in infant formula and pharmaceutical products, as well as Ocean Gold refined tuna oils. Its products include DHA oils, DHA powders, and other nutritional oils drawn from patented microencapsulation technologies. Geographically, the group has a business presence in Australia, New Zealand, Asia, Europe, and the Americas. The majority of the company's revenue is derived from the Asian market.
CLV Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
20 Dec 2024 | $0.42 | $-0.02 | -4.55% | 23,088 | $0.42 | $0.42 | $0.42 |
19 Dec 2024 | $0.44 | $0.01 | 2.30% | 60,999 | $0.45 | $0.46 | $0.44 |
18 Dec 2024 | $0.44 | $0.01 | 2.35% | 1,530 | $0.44 | $0.44 | $0.44 |
17 Dec 2024 | $0.43 | $-0.03 | -6.67% | 608,707 | $0.45 | $0.45 | $0.43 |
13 Dec 2024 | $0.45 | $0.01 | 2.25% | 500 | $0.45 | $0.45 | $0.45 |
12 Dec 2024 | $0.45 | $-0.03 | -6.32% | 2,288 | $0.46 | $0.46 | $0.45 |
11 Dec 2024 | $0.48 | $0.03 | 6.70% | 18,761 | $0.44 | $0.48 | $0.44 |
10 Dec 2024 | $0.45 | $-0.01 | -2.17% | 4,875 | $0.44 | $0.45 | $0.44 |
09 Dec 2024 | $0.46 | $0.00 | 0.00% | 1,375 | $0.46 | $0.46 | $0.46 |
06 Dec 2024 | $0.46 | $-0.01 | -2.13% | 5,749 | $0.44 | $0.46 | $0.44 |
05 Dec 2024 | $0.47 | $0.00 | 0.00% | 14,035 | $0.47 | $0.47 | $0.47 |
04 Dec 2024 | $0.47 | $-0.01 | -2.11% | 28,849 | $0.48 | $0.48 | $0.47 |
03 Dec 2024 | $0.48 | $-0.01 | -2.08% | 11,131 | $0.48 | $0.48 | $0.48 |
02 Dec 2024 | $0.48 | $-0.01 | -2.06% | 156 | $0.48 | $0.48 | $0.48 |
29 Nov 2024 | $0.49 | $0.00 | 0.00% | 69,122 | $0.49 | $0.49 | $0.49 |
28 Nov 2024 | $0.49 | $0.00 | 0.00% | 123,374 | $0.49 | $0.49 | $0.49 |
26 Nov 2024 | $0.49 | $0.00 | 0.00% | 124,939 | $0.49 | $0.49 | $0.49 |
25 Nov 2024 | $0.49 | $0.00 | 0.00% | 48,141 | $0.49 | $0.49 | $0.48 |
22 Nov 2024 | $0.49 | $0.00 | 0.00% | 29,704 | $0.48 | $0.49 | $0.48 |
21 Nov 2024 | $0.49 | $0.02 | 4.26% | 21,141 | $0.48 | $0.49 | $0.48 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
22 Nov 2024 | Peter Davey | Buy | 35,144 | $17,044 |
On-market trade.
|
22 Nov 2024 | Peter Davey | Buy | 582,356 | $282,442 |
On-market trade. 1,087,267 Performance Rights
|
22 Nov 2024 | Peter Davey | Expiry | 140,575 | $68,178 |
As advised by the company. Lapsed, 504,911 Rights
|
06 Nov 2024 | Simon Green | Buy | 20,000 | $10,898 |
On-market trade.
|
25 Sep 2024 | Rupert Harrington | Buy | 40,162 | $18,477 |
On-market trade.
|
03 Apr 2024 | Rupert Harrington | Buy | 200,000 | $99,992 |
On-market trade.
|
28 Mar 2024 | Peter Davey | Buy | 10,000 | $5,030 |
On-market trade.
|
28 Mar 2024 | Ian Glasson | Buy | 20,000 | $10,030 |
On-market trade.
|
22 Mar 2024 | Toni Brendish | Buy | 16,400 | $10,046 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Ian David Glasson | Non-Executive Director | Feb 2017 |
Mr Glasson is former CEO of PGG Wrightson based in Christchurch, New Zealand. He was formerly CEO of Gold Coin Group / Zuellig Agriculture which managed a portfolio of animal feed operations and farming ventures throughout South East Asia. Prior to that he was CEO for seven years of Sucrogen (formerly the sugar business of listed entity CSR and now owned by Wilmar) which generated revenues of nearly $2 billion and had extensive contacts across the local and international food and beverage sector and retail market. He has also had agribusiness experience with Goodman Fielder and Gresham Rabo, as well as spending the first sixteen years of his career in the oil and gas sector with Esso.
|
Ms Toni Brendish | Non-Executive Director | Oct 2020 |
Ms Brendish has more than 30 years' experience working in blue chip FMCG, healthcare, manufacturing, agriculture, and telecommunication companies in Asia, Australia, and New Zealand, including over 20 years in Chief Executive Officer / Managing Director roles. Toni Brendish' s most recent executive role was as Chief Executive Officer of Westland Milk Products in the South Island of New Zealand. Prior to this, Toni spent 11 years working for the Danone Group as Managing Director of their Infant Formula and Dairy businesses in Australia, New Zealand, Malaysia and Indonesia. She has also worked for Kimberly-Clark and Colgate Palmolive, together with a number of other blue chip FMCG organisations. She was appointed as a shareholder representative director on the board of Prolife Foods, a private New Zealand consumer foods business with brands including Mother Earth and Scoop and Weigh. Toni is also on the board advisory committee for dairy farming and milk producers, Aurora Dairies.
|
Mr Rupert Anthony Harrington | Non-Executive DirectorNon-Executive Chairman | Jul 2015 |
Mr Harrington is an experienced company Director with over 30 years of experience as a Non-Executive Director of companies operating in manufacturing, industrial services, health and technology. He has been involved in private equity since 1987 and is considered to be one of the founders of the Australian industry. Mr Harrington was previously a Non Executive Director of Bradken Limited, Advent Partners and others.
|
Mr Graeme Ambery Billings | Non-Executive Director | May 2013 |
Mr Billings was a partner at Coopers and Lybrand and then PricewaterhouseCoopers (PwC) for 24 years. Mr Billings was head of PwC's Melbourne Assurance practice for several years as well as Global Leader of PwC's Industrial Products and Manufacturing industry group. Mr Billings brings a range of financial, corporate governance, internal control, commercial and corporate transactional skills to the Company. Previously, Graeme was Chairman of Korvest Ltd (resigned in August 2021) and a Non-Executive Director and Audit Committee Chair of DomaCom Ltd (resigned in June 2021).
|
Mr Peter J Davey | Chief Executive OfficerManaging Director | Dec 2014 |
Mr Davey has a record of building businesses across a range of industry sectors. He has held senior management positions within a number of manufacturing and distribution companies operating in competitive and markets. Mr Davey has strengths in sales and marketing, and development and implementation of strategies for growth. Mr Davey was formerly Executive Manager AgriProducts and a director of Viterra Australia Limited, responsible for the AgriProducts division that traded in agricultural inputs, fertilizer, seed and wool. In earlier roles, Mr Davey headed the Sales and Marketing divisions of FMP Products and Hi Fert Pty Ltd. During his career, Mr Davey has had a focus on marketing-based businesses operating in the Asia and Oceania regions. Other current Non-Executive Company directorships: Chairman Melody Dairies Ltd Partnership, appointed 30 October 2018.
|
Dr Simon Green | Non-Executive Director | Oct 2020 |
Dr Green has 32 years of experience in the biotechnology industry focused on the discovery, development and commercialisation of life saving medicines. He was involved in CSL's global expansion over a 17-year period and held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL's manufacturing plants in Germany and Australia. Simon is currently the founder and CEO of Immunosis Pty Ltd, a start-up diagnostics Company.
|
Mr Andrew Allibon | Chief Financial OfficerCompany Secretary | May 2021 |
-
|
Andrew Allibon | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Washington H Soul Pattinson & Company Limited | 32,717,159 | 19.59% |
Citicorp Nominees Pty Limited | 22,108,065 | 13.24% |
Ubs Nominees Pty Ltd | 16,414,463 | 9.83% |
HSBC Custody Nominees (Australia) Limited | 13,359,928 | 8.00% |
Anacacia Pty Ltd | 11,618,012 | 6.96% |
Evelin Investments Pty Limited | 7,550,000 | 4.52% |
J P Morgan Nominees Australia Pty Limited | 7,427,140 | 4.45% |
Incani & Papadopoulos Super Pty Ltd | 2,010,000 | 1.20% |
Mr Peter Howells | 1,380,000 | 0.83% |
Ganesh Super Fund | 1,128,457 | 0.68% |
BNP Paribas Noms Pty Ltd | 1,127,044 | 0.67% |
Neweconomy Com Au Nominees Pty Limited | 960,983 | 0.58% |
Mr Garrie Ellice | 960,000 | 0.57% |
Mr Pei Yin Foo | 900,000 | 0.54% |
BNP Paribas Noms (Nz) Ltd | 870,430 | 0.52% |
Baobab Nominees Pty Ltd | 861,011 | 0.52% |
Ms Nina Tschernykow | 858,881 | 0.51% |
Morgan Stanley Aust Securities (Nominee) Pty Ltd | 783,764 | 0.47% |
Connaught Consultants (Finance) Pty Ltd | 741,000 | 0.44% |
HSBC Custody Nominees (Australia) Limited A/C2 | 719,184 | 0.43% |